Fc Receptor (FcR)

Fc Receptor

Fc Receptors (FcR) are a class of cell surface receptors that can recognize and bind to the Fc region of immunoglobulins, playing an important role in processes such as the immune response and immune regulation. According to the types of immunoglobulins they recognize, FcR can be classified into FcγR, FcεR, FcαR, etc. According to their functional characteristics, they can be divided into activating FcR and inhibitory FcR. FcR mediate the phagocytosis of immune cells, prompting phagocytes to eliminate antigenic foreign substances such as pathogens. FcR also participate in ADCC, which activates NK cells and other cells to kill target cells, affecting the immune response. In addition, FcR can clear immune complexes and prevent them from depositing in tissues and triggering inflammation. Abnormal functions or dysregulated expressions of FcR can lead to autoimmune diseases and allergic diseases. In tumors, FcR are involved in both the immune escape of tumor cells and can serve as targets for immunotherapy^[1]^[2].

References:

[1]. Raghavan M, et al. Fc receptors and their interactions with immunoglobulins. Annu Rev Cell Dev Biol. 1996;12:181-220.

[2]. Bruhns P, et al. Mouse and human FcR effector functions. Immunol Rev. 2015 Nov;268(1):25-51. [Content Brief]

Fc Receptor (FcR) Related Products (19):

By Effects:	Inhibitors (10) Ligand (1) Antagonists (3)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-P99037

Nipocalimab	Ligand	99.90%
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases.

HY-P99009

Batoclimab	Inhibitor	99.89%
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease.

HY-P99979

Rat IgG1 kappa, Isotype Control		99.90%
Rat IgG1 kappa, Isotype Control, a rat monoclonal antibody, is an isotype control for Rat IgG1κ antibody.

HY-P99300

Ligelizumab	Inhibitor	99.85%
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma).

HY-P99125

Anti-Mouse CD16/CD32 Antibody (2.4G2)	Inhibitor
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for research on atherosclerosis and autoimmune hematological disorders.

HY-147305

Efgartigimod alfa	Inhibitor
Efgartigimod alfa (ARGX-113) is a neonatal Fc receptor (FcRn) blocker. Efgartigimod alfa is an anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod alfa can be used for the research of myasthenia gravis.

HY-P991086

MGD010	Inhibitor
MGD010 is a bispecific CD32B (FcγRIIb) and CD79B antibody. MGD010 inhibits activated B-cells by delivering a negative signal via simultaneous co-ligation of CD32B (FcγRIIb), with the BCR component, CD79B. MGD010 has the potential for the study of autoimmune disorders.

HY-P991165

Trovostobart
Trovostobart is an anti-VSIR human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990676

VIB-9600	Inhibitor	99.41%
VIB-9600 is a humanized antibody expressed in CHO cells, targeting FcgR2a/CD32a. VIB-9600 has a huIgG1 type heavy chain and huκ type light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for VIB-9600 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P99529

Valziflocept		99.00%
Valziflocept (BAX1810; TAK-752) is a recombinant soluble human FcγRIIb receptor that targets Fc and FcγR. FcγRs bind and neutralize pathogenic IgG, thus forming a "decoy" or "scavenger" receptor that can reduce the severity of autoimmune diseases. Valziflocept can be used in studies of autoimmune diseases such as systemic lupus erythematosus (SLE).

HY-P99996

Human IgG1 (D265A) kappa, Isotype Control		99.6%
Human IgG1 (D265A) kappa, Isotype Control, a human-derived antibody, is an isotype control for human IgG1 (D265A)κ antibody.

HY-P990413

Anti-Fc gamma R1 Antibody	Inhibitor
The Anti-Fc gamma R1 Antibody is a human-derived antibody expressed in CHO, targeting Fc gamma R1. The Anti-Fc gamma R1 Antibody features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 150 kDa. For the isotype control of the Anti-Fc gamma R1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-145775

hIgG-hFc receptor-IN-1	Inhibitor
hIgG–hFc receptor-IN-1 (comp 66) is a human immunoglobulin G–human neonatal Fc receptor (hIgG–hFcRn) protein-protein interaction inhibitor, with an IC₅₀ of 2 μM .

HY-158316

BTL-MK	Inhibitor
BTL-MK (Compound 19) an orally active antiallergic agent, that inhibits degranulation of mast cells with an IC₅₀ of 6.7 μM, through binding to the inhibitory receptor FcγRIIB. BTL-MK improves the metaboilic stability in human liver microsomes. BTL-MK ameliorates the allergic response in Ovalbumins (HY-W250978)-induced food allergy mice model. BTL-MK exhibits a good pharmacokinetic character with metabolic stability.

HY-P991582

BI-1607	Antagonist
BI-1607 is a humanized monoclonal antibody targeting CD32b/FcγRIIB. BI-1607 has an antagonistic function capable of blocking the inhibitory function of FcγRIIB on immune effector cells. BI-1607 has a significant cytolytic activity against malignant B cells and antitumor activity against HER2-positive solid tumors including advanced gastric cancer (GC) with combination with Trastuzumab (HY-P9907).

HY-P991225

BI-1206	Antagonist
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL).

HY-P991476

MDX-220	Antagonist
MDX-220 is a human monoclonal antibody (mAb) targeting FcRn. MDX-220 has anti-tumor activity.

HY-P990244

Anti-Rat FcRn heavy chain heterodimers Antibody (2G3)	Inhibitor
Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is a mouse-derived IgG1 type antibody inhibitor, targeting to rat FcRn heavy chain heterodimers.

HY-P991502

Armenian hamster IgG1 kappa, Isotype Control
Armenian hamster IgG1 kappa, Isotype Control, a Armenian hamster monoclonal antibody, is an isotype control for Armenian hamster IgG1 kappa antibody.

Name
Email *

	Sorry, but the email address you supplied was invalid.